简化版滤泡性淋巴瘤PRIMA预后指数在一线无化疗利妥昔单抗为基础治疗患者中有用
在291例接受前瞻性随机北欧淋巴瘤组试验(利妥昔单抗±干扰素)的初治症状性/进展性滤泡性淋巴瘤患者中,PRIMA-PI对至治疗失败时间和总生存均有预后价值,高危组风险显著高于低危组;FLIPI仅对总生存有预后价值。
要点
- PRIMA-PI高危组至治疗失败时间HR 1.90(95%CI 1.30-2.78,P=0.001),总生存HR 3.19(95%CI 1.75-5.83,P<0.001)。
- FLIPI风险组仅对总生存有预后价值(log-rank P=0.018)。
- PRIMA-PI高危组患者应考虑替代治疗。
核心结论
- 简化PRIMA-PI在含利妥昔单抗无化疗一线治疗的滤泡性淋巴瘤队列中有效,风险分层优于FLIPI,尤其在年龄>60岁患者中。
- PRIMA-PI高危组患者应考虑替代治疗。
研究设计与样本
- 研究纳入291例初治、症状性/进展性滤泡性淋巴瘤患者,接受两项前瞻性随机北欧淋巴瘤组试验的利妥昔单抗±干扰素治疗。
主要发现
- PRIMA-PI对至治疗失败时间和总生存均有预后价值(log-rank P=0.003和P<0.001)。
- PRIMA-PI高危组至治疗失败时间HR 1.90(95%CI 1.30-2.78,P=0.001),总生存HR 3.19(95%CI 1.75-5.83,P<0.001),均较低危组差。
- FLIPI风险组仅对总生存有预后价值(log-rank P=0.018)。
关键数值与推荐
- PRIMA-PI高危组至治疗失败时间HR 1.90(95%CI 1.30-2.78,P=0.001),总生存HR 3.19(95%CI 1.75-5.83,P<0.001)。
- PRIMA-PI对至治疗失败时间log-rank P=0.003,对总生存log-rank P<0.001。
- FLIPI对总生存log-rank P=0.018。
临床怎么用
- 作者认为PRIMA-PI高危组患者应考虑替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA-PI was built on rituximab chemotherapy. Our objective was to evaluate these two prognostic tools in a cohort of 291 patients with FL treated in two prospective randomised Nordic Lymphoma Group trials with rituximab ± interferon. All patients had symptomatic/progressive disease and were previously untreated. The PRIMA-PI was prognostic for both time to treatment failure (TTF) and overall survival (OS) (log-rank P = 0·003 and P < 0·001, respectively). The PRIMA-PI high-risk identified a small group of patients with a very short TTF and OS compared to the low-risk group, with a hazard ratio (HR) of 1·90 (95% confidence interval [CI] 1·30-2·78, P = 0·001) and HR of 3·19 (95% CI 1·75-5·83, P < 0·001), respectively. The FLIPI risk groups were prognostic only for OS (log-rank P = 0·018). The simplified PRIMA-PI was valid in our FL cohort with first-line rituximab-containing chemo-free therapy and shows an improved risk stratification compared to the FLIPI, especially in patients aged >60 years. Patients in the PRIMA-PI high-risk group should be considered for alternative therapies.
引用
- Kimby E, Lockmer S, Holte H, et al. The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy. Br J Haematol. 2020. PMID: 32410260. doi:10.1111/bjh.16692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。